Alphatec Holdings, Inc.

Alphatec Holdings, Inc.(ATEC)股票分析

$10.440

-0.366 (-3.51%)收盤時

Loading chart…
最高
10.810
開盤
10.630
成交量加權均價
10.52
成交量
1.76M
市值
1.45B
最低
10.310
成交金額
18.53M
企業價值/稅息折舊攤銷前利潤(TTM)
28.65

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.

AI 分析 of Alphatec Holdings, Inc. (ATEC)

買進

Alphatec Holdings Inc (ATEC) is a good buy right now due to its current price of $10.67, which is below the analyst price targets ranging from $12 to $15. The stock has shown a recent 5-day change of +6.38%, indicating positive momentum, and the RSI is at 62.93, suggesting it is not overbought. However, the company has a significant risk with a forward P/E ratio of 18.55, indicating potential overvaluation concerns if earnings do not improve.

分析師評級(3)

上檔空間 +133.05%
買進
2 買進
1 持有
0 賣出
目前: 10.44
最低
20.00
平均
24.33
最高
28.00

BMO Capital

2026-08-05

目標價

$12

優於大盤

UBS

2026-07-28

目標價

$15

買進

Stephens

2026-07-23

目標價

$15

增持

Stifel

2026-07-08

目標價

$13

買進

Barclays

2026-05-07

目標價

$24

增持

估值指標

Alphatec Holdings, Inc.(ATEC)目前預期本益比為 18.55,5 年平均預期本益比為 15.65。

預期本益比

合理
5 年均值 P/E
15.65
目前P/E
18.55
高估
107.43
低估
-76.14

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
69.77
目前EV/EBITDA
28.65
高估
254.22
低估
-114.67

預期股價營收比

低估
5 年均值 P/S
2.60
目前P/S
1.58
高估
3.43
低估
1.76

Alphio AI 對 ATEC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ATEC

$14.87

情境價格

基

基準

基準 · 50%ATEC

$14.86

情境價格

悲

悲觀

悲觀 · 25%ATEC

$14.36

情境價格

持有 ATEC 的大戶

B

Braidwell LP

+ 持有ATEC

+13.80%

3個月報酬率

T

Tremblant Capital Group

+ 持有ATEC

+0.74%

3個月報酬率

事件時間軸

2026-09-11 (ET)

12:00:00

Major Averages Rebound as Oil Prices Retreat

2026-08-04 (ET)

17:00:00

ATEC Reports Q2 Revenue of $214M, Exceeds Expectations

17:00:00

Company Reaffirms FY2026 Revenue Outlook, Raises EBITDA Guidance to $140 Million

2026-05-05 (ET)

16:50:00

ATEC Reports Q1 Revenue of $192.1M, Below Expectations

16:50:00

Company Expects Total Revenue of $882 Million for Fiscal Year 2026

資訊

ATEC 常見問題 —— 由 Alphio AI 解答

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. It is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. Its Organic Innovation Machine is focused on developing new approaches that integrate with its expanding InformatiX Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include InformatiX, positioners, access systems, implants and fixation systems, and biologics. Its InformatiX product platform comprises EOS imaging system, EOS Insight alignment assessment and surgical planning web/mobile platform, SafeOp Neural InformatiX System and navigation-enabled robotics platform. It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Alphatec Holdings Inc (ATEC) is a good buy right now due to its current price of $10.67, which is below the analyst price targets ranging from $12 to $15. The stock has shown a recent 5-day change of +6.38%, indicating positive momentum, and the RSI is at 62.93, suggesting it is not overbought. However, the company has a significant risk with a forward P/E ratio of 18.55, indicating potential overvaluation concerns if earnings do not improve.

3 analysts cover ATEC: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 24.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易